Related Experiment Video
Updated: Oct 10, 2026
Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae
Published on: January 17, 2014
Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the
M Duong1, M Simard, Y Bergeron
1Centre de Recherche en Infectiologie, Centre Hospitalier de l'Université Laval, and Département de Microbiologie, Faculté de Médecine, Université Laval, Sainte Foy, Québec, Canada G1V 4G2.
Abstract:
Patients still die from Streptococcus pneumoniae pneumonia after initiation of antibiotic therapy, when tissues are sterile and the pneumonia is clearing. There is growing evidence that overwhelming inflammation resulting from toxin release contributes to tissue injury, shock, and death. Monitoring host response may help us understand the consequences of antibiotic therapy for the inflammatory processes that occur in bacterial pneumonia. HMR 3004 is a ketolide that displays excellent in vitro activity against S. pneumoniae. In the present experiment, we investigated the chronology of inflammatory events that occur during pneumococcal pneumonia in mice treated with HMR 3004. Infection of mice with 10(7) CFU of living S. pneumoniae resulted in 100% mortality within 5 days. HMR 3004 given at 12.5 mg/kg of body weight/dose twice daily from 48 h postinfection achieved complete bacterial clearance from lungs and blood within 36 h and ensured survival of mice. Recruitment of neutrophils and monocytes from blood to lungs was significantly reduced, and nitric oxide release was totally prevented. Interleukin-6 secretion in lungs and blood became rapidly undetectable after initiation of therapy. Histological examination of lung tissue showed protection of interstitium against edema. By controlling bacterial invasion, HMR 3004 led to rapid and profound modifications of the host response in lungs, which may protect mice from deleterious inflammatory reactions.
Insights
This study shows that HMR 3004, a ketolide antibiotic, effectively clears Streptococcus pneumoniae in mice. It also significantly reduces harmful inflammation, preventing mortality in severe pneumonia cases.
Area of Science:
- Microbiology
- Immunology
- Pharmacology
Background:
- Streptococcus pneumoniae pneumonia can be fatal despite antibiotic treatment, with inflammation and toxin release contributing to mortality.
- Understanding the host response to antibiotic therapy is crucial for managing bacterial pneumonia.
- Ketolide antibiotics, like HMR 3004, show promise against S. pneumoniae.
Purpose of the Study:
- To investigate the inflammatory events during pneumococcal pneumonia in mice treated with HMR 3004.
- To evaluate the impact of HMR 3004 on host response and survival.
Main Methods:
- Mice were infected with S. pneumoniae, and HMR 3004 treatment was initiated 48 hours postinfection.
- Bacterial clearance, inflammatory cell recruitment, cytokine levels (Interleukin-6), nitric oxide release, and lung histology were assessed.
- Survival rates were monitored.
Main Results:
- HMR 3004 achieved complete bacterial clearance in lungs and blood within 36 hours, ensuring mouse survival.
- Neutrophil and monocyte recruitment to the lungs was significantly reduced.
- Nitric oxide release was prevented, and Interleukin-6 levels decreased rapidly. Lung edema was also reduced.
Conclusions:
- HMR 3004 effectively controls bacterial invasion in S. pneumoniae pneumonia.
- The drug profoundly modifies the host inflammatory response, protecting against detrimental reactions.
- HMR 3004 demonstrates potential as a therapeutic agent for severe pneumococcal pneumonia by mitigating inflammation.
More Related Videos
08:25Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
